[Bio-safety testing for retroviral vector as gene therapy delivery system]

Area of Science:

• Molecular Biology
• Virology
• Biotechnology

Context:

• Gene therapy offers a promising approach for treating chronic hepatitis B virus (HBV) infections.
• Intracellular immunization strategies are being explored to combat HBV.
• Rigorous bio-safety assessments are critical for the clinical translation of gene therapy vectors.

Purpose:

• To establish a comprehensive bio-safety testing system for gene therapy targeting HBV.
• To validate methods for detecting sterility, mycoplasma contamination, and replication-competent retroviruses (RCR).

Summary:

• A bio-safety testing system was developed, incorporating sterility, mycoplasma, and RCR detection.
• Polymerase chain reaction (PCR) was used for mycoplasma detection.
• S+/L- assay, NIH3T3 amplification, and neo gene rescue assay were employed for RCR determination.
• All packaging cell lines were confirmed negative for bacterial and fungal contamination.
• One cell line tested positive for mycoplasma; however, no RCR was detected in any cell line.

Impact:

• The developed methods are stable and sensitive, suitable for bio-safety testing in gene therapy clinical trials.
• This system enhances the safety profile of gene therapy applications for HBV.
• Provides a reliable framework for quality control in the production of gene therapy vectors.